摘要
目的观察孟鲁司特钠联合沙美特罗替卡松治疗支气管哮喘的临床效果。方法选取2021年6月—2024年6月广西医科大学第一附属医院收治的支气管哮喘患者100例,以双色球法随机分为观察组和对照组各50例。对照组给予沙美特罗替卡松治疗,观察组在对照组基础上给予孟鲁司特钠治疗,2组均持续治疗2周。比较2组近期治疗效果、症状体征缓解时间,治疗前后肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))]、炎性指标[C反应蛋白(CRP)、嗜酸性粒细胞计数(E)、呼气一氧化氮浓度(FeNO)]、免疫功能指标(CD3^(+)、CD4^(+)/CD8^(+)),不良反应及随访6个月复发率。结果观察组治疗总有效率为96.00%,高于对照组的82.00%(χ^(2)=5.005,P=0.025)。观察组咳嗽、喘息、哮鸣音、胸闷缓解时间均短于对照组(P<0.01)。治疗2周后,2组FVC、FEV_(1)高于治疗前,且观察组高于对照组(P<0.01);2组CRP水平及E、FeNO低于治疗前,且观察组低于对照组(P<0.01);2组CD3^(+)组内、组间比较及对照组CD4^(+)/CD8^(+)治疗前后比较差异均无统计学意义(P>0.05),观察组CD4^(+)/CD8^(+)高于治疗前及同期对照组(P<0.01)。观察组与对照组不良反应总发生率比较差异无统计学意义(6.00%vs.4.00%,χ^(2)=0.211,P=0.646)。随访6个月,观察组复发率为6.00%,低于对照组的20.00%(χ^(2)=4.332,P=0.037)。结论孟鲁司特钠联合沙美特罗替卡松治疗支气管哮喘效果较好,有利于疾病控制,改善肺功能及免疫功能,减轻炎性反应,且不良反应少,复发率低。
Objective To observe the clinical effect of montelukast sodium combined with salmeterol fluticasone in the treatment of bronchial asthma.Methods One hundred patients with bronchial asthma admitted to the First Affiliated Hospital of Guangxi Medical University from June 2021 to June 2024 were selected and randomly divided into an observation group and a control group by the double color ball method,with 50 cases in each group.The control group was treated with salmeterol fluticasone,and the observation group was treated with montelukast sodium on the basis of the control group,both groups were treated continuously for 2 weeks.The short-term therapeutic effects,symptom and signs relief time,pulmonary function indicators(FVC,FEV_(1)),inflammatory indicators(CRP,E,FeNO),immune function(CD3^(+),CD4^(+)/CD8^(+))before and a fter treatment,adverse reactions and recurrence rate at 6-month follow-up were compared between two groups.Results The total effective rate of treatment in the observation group was 96.00%,which was higher than 82.00%in the control group(χ^(2)=5.005,P=0.025).The relief time of cough,wheezing,wheezing sound and chest tightness in the observation group were shorter than those in the control group(P<0.01).After 2 weeks of treatment,FVC and FEV_(1)in both groups were higher than those before treatment,and the observation group was higher than the control group(P<0.01).The levels of CRP and E,FeNO in both groups were lower than those before treatment,and the observation group were lower than those in the control group(P<0.01).There was no statistically significant difference in the intra-group and inter-group comparisons of CD3^(+)in the two groups and the comparison of CD4^(+)/CD8^(+)in the control group before and after treatment(P>0.05).The CD4^(+)/CD8^(+)in the observation group was higher than that before treatment and control group in the same period(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the observation group and the control group(6.00%vs.4.00%,χ^(2)=0.211,P=0.646).After a 6-month follow-up,the recurrence rate in the observation group was 6.00%,which was lower than 20.00%in the control group(χ^(2)=4.332,P=0.037).Conclusion Montelukast sodium combined with salmeterol fluticasone has a better effect in the treatment of bronchial asthma.It is beneficial for disease control,improving lung function and immune function,reducing inflammatory responses,and has few adverse reactions and a low recurrence rate.
作者
杨宇翔
李超乾
YANG Yuxiang;LI Chaoqian(Department of Respiratory Medicine,the First Affiliated Hospital of Guangxi Medical University,Nanning 530000,China)
出处
《临床合理用药》
2025年第16期1-4,共4页
Chinese Journal of Clinical Rational Drug Use
基金
国家自然科学基金项目(8236010404)。
关键词
支气管哮喘
孟鲁司特钠
沙美特罗替卡松
肺功能
炎性指标
Bronchial asthma
Montelukast sodium
Salmeterol fluticasone
Lung function
Inflammatory indicators
